No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients

Acta Oncologica

Volumn 53, Issue 2, 2014, Pages 195-200

  Markkula, Andrea ^a   Hjertberg, Maria ^a,b   Rose, Carsten ^a   Ingvar, Christian ^a   Jernström, Helena ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b VRINNEVI HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; TAMOXIFEN; AROMATASE INHIBITOR; CYTOCHROME P450 2D6 INHIBITOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; COMPARATIVE STUDY; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; POPULATION; PRIORITY JOURNAL; QUESTIONNAIRE; SWEDEN; TREATMENT OUTCOME; BODY HEIGHT; BODY WEIGHT; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; IMMUNOHISTOCHEMISTRY; PROSPECTIVE STUDY; TREATMENT DURATION; TUMOR VOLUME; WAIST HIP RATIO;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; DISEASE-FREE SURVIVAL; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SWEDEN; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84892183086     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.840739     Document Type: Article

References (25)

1. Youlden DR , C ramb SM , D unn NA , M uller JM , P yke CM , Baade PD . The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality . Cancer Epidemiol 2012 ; 36 : 237-48
2. National Board of Health and Welfare. C ancer i Siffror 2009 (Information about cancer incidence and survival in Sweden) . 2009
3. Early Breast Cancer Trialists' Collaborative Group E. E ffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials . Lancet 2005 ; 365 : 1687-717
4. Lash T L , L ien E A , S orensen H T , H amilton-Dutoit S . Genotype-guided tamoxifen therapy: Time to pause for refl ection? Lancet Oncol 2009 ; 10 : 825-33
5. Hertz D L , M cLeod H L, I rvin W J, J r . T amoxifen and CYP2D6: A contradiction of data . Oncologist 2012 ; 17 : 620-30
6. Jin Y , D esta Z , S tearns V , W ard B , H o H , L ee K H, e t al . CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment . J Natl Cancer Inst 2005 ; 97 : 30-9
7. Borges S , D esta Z, L i L, S kaar T C , W ard BA, N guyen A , et al . Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment . Clin Pharmacol Ther 2006 ; 80 : 61-74
8. Margolin S , L indh J D , T horen L , X ie H , K oukel L, Dahl ML , et al . CYP2D6 and adjuvant tamoxifen: Possible differences of outcome in pre-and post-menopausal patients . Pharmacogenomics 2013 ; 14 : 613-22
9. Wegman P , V ainikka L, S t ål O, N ordenskj öl d B, S koog L, Rutqvist LE , et al . Genotype of metabolic enzymes and the benefi t of tamoxifen in postmenopausal breast cancer patients . Breast Cancer Res 2005 ; 7 : R284-90
10. Wegman P , E lingarami S , C arstensen J, S t ål O, Nordenskj ö ld B , Wingren S . Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer . Breast Cancer Res 2007 ; 9 : R7
11. Lundin KB, H enningson M , H ietala M , I ngvar C , R ose C, Jernstr ö m H . Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients . Br J Cancer 2011 ; 105 : 1676-83
12. Bå g eman E, I ngvar C, R ose C, J ernstr öm H . C offee consumption and CYP1A2 ? 1F genotype modify age at breast cancer diagnosis and estrogen receptor status . Cancer Epidemiol Biomarkers Prev 2008 ; 17 : 895-901
13. Flockhart D A . D rug interactions: Cytochrome P450 drug interaction table: Indiana University School of Medicine (2007)
14. Blake MJ , G aedigk A , P earce RE , B omgaars LR , C hristensen ML , Stowe C . et al . Ontogeny of dextromethorphan O-and N-demethylation in the fi rst year of life . Clin Pharmacol Ther 2007 ; 81 : 510-6
15. Rae JM , S ikora MJ , H enry NL , L i L, K im S , O esterreich S , et al . Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients . Pharmacogenomics J 2009 ; 9 : 258-64
16. Lash TL , C ronin-Fenton D , A hern TP , R osenberg C L, Lunetta KL , Silliman RA , et al . CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark . J Natl Cancer Inst 2011 ; 103 : 489-500
17. Ahern T P , P edersen L , C ronin-Fenton D P , S orensen HT , Lash TL . No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications . Cancer Epidemiol Biomarkers Prev 2009 ; 18 : 2562-4
18. Goetz MP , K nox SK , S uman VJ , R ae JM , S afgren SL , Ames MM , et al . The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen . Breast Cancer Res Treat 2007 ; 101 : 113-21
19. Regan M M , L eyland-Jones B , B ouzyk M , P agani O , T ang W, Kammler R , et al . CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial . J Natl Cancer Inst 2012 ; 104 : 441-51
20. Ingelman-Sundberg M , S im SC , G omez A , R odriguez-Antona C . Infl uence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects . Pharmacol Ther 2007 ; 116 : 496-526
21. Walsky RL , G aman EA , O bach RS . E xamination of 209 drugs for inhibition of cytochrome P450 2C8 . J Clin Pharmacol 2005 ; 45 : 68-78
22. Desmarais JE, L ooper KJ . I nteractions between tamoxifen and antidepressants via cytochrome P450 2D6 . J Clin Psychiatry 2009 ; 70 : 1688-97
23. Schroth W, A ntoniadou L, F ritz P , S chwab M , M uerdter T , Zanger UM , et al . Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes . J Clin Oncol 2007 ; 25 : 5187-93
24. Jernstr öm H, B å g eman E , R ose C, J ö n sson P-E , I ngvar C . CYP2C8 and CYP2C9 polymorphisms in relation to tumor characteristics and early breast cancer related events among 652 breast cancer patients . Br J Cancer 2009 ; 101 : 1817-23
25. Simonsson M , S ö derlind V , H enningson M , H jertberg M , Rose C , Ingvar C , et al . Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status . Cancer Causes Control 2013 ; 24 : 929-40 .